New hope for EU patent plan

A planned redesign of the European patent system, announced last week (December 4th), could reduce the cost and strengthen the legal weight of European patents -- a change that biotechnology companies have long awaited. Image: WikipediaCurrently, a European patent can cost companies up to 11 times as much as they would pay in the United States, while providing far fewer legal certainties. The existing patent system is simply a bundle of 4-6 national patents; applicants must choose the countries

Written byEdyta Zielinska
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share
A planned redesign of the European patent system, announced last week (December 4th), could reduce the cost and strengthen the legal weight of European patents -- a change that biotechnology companies have long awaited.

Image: Wikipedia
Currently, a European patent can cost companies up to 11 times as much as they would pay in the United States, while providing far fewer legal certainties. The existing patent system is simply a bundle of 4-6 national patents; applicants must choose the countries in which they most want their patent to apply, rather than receiving a patent that extends to all of the EU member nations, explained Ilias Konteas, a legal advisor to BusinessEurope, a group that represents EU companies. The bundled system "raises questions of legal certainty," said Konteas, because "you can have [contested] patents enforced by one country and not another." The new proposal would create a single patent covering all EU member nations. It also stipulates creating a European patent court which would consider challenges to any patent under a single law. While the proposal appears to have the backing of the member states, said Willy De Greef, the Secretary General of EuropaBio, a trade organization for European biotechnology companies, it will need to undergo an official review by the European Council and the European Parliament before being passed into law. After nearly a decade of deliberations among the EU members, the proposal is a major step forward, said De Greef. "The last time [the patent proposal] was getting close to agreement, it stumbled over the language issue," De Greef said. While most of the member states could agree on the need for a unified court system, the group couldn't settle on which language or languages the patent documents should be written in, he said. With 21 languages in the EU, the issue "is so much connected to culture and history," he said "that we have to tread very carefully." As it stands now, the current proposal leaves the language question open. But the agreement over establishing a European court "revives our confidence that [the EU] means what it says about the innovation agenda," said De Greef. "We are enthusiastically behind it."
**__Related stories:__***linkurl:EU trial rules stall research;http://www.the-scientist.com/blog/display/56149/
[17th November 2009]*linkurl:EU moves to unify science;http://www.the-scientist.com/blog/display/56042/
[6th October 2009]*linkurl:EU animal research under fire;http://www.the-scientist.com/blog/display/55523/
[25th March 2009]
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies